Literature DB >> 3232784

Intravenous fluids in minor gynaecological surgery. Their effect on postoperative morbidity.

E M Spencer1.   

Abstract

Postoperative morbidity was assessed in 100 patients who underwent minor gynaecological procedures. Fifty patients received intra-operative crystalloid (1000 ml compound sodium lactate solution) and the remaining fifty none. Identical short-acting intravenous anaesthetic techniques were used in both groups. There was no statistically significant difference between the groups in symptoms of nausea, vomiting, headache and drowsiness within the first 6 hours after operation. Patients who received intra-operative fluids exhibited a decreased incidence of dizziness within the first 6 hours and a decreased incidence of nausea when questioned at 3 days compared with those who did not receive any fluid; the difference was statistically significant.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3232784     DOI: 10.1111/j.1365-2044.1988.tb05708.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  11 in total

1.  Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial.

Authors:  Birgitte Brandstrup; Hanne Tønnesen; Randi Beier-Holgersen; Else Hjortsø; Helle Ørding; Karen Lindorff-Larsen; Morten S Rasmussen; Charlotte Lanng; Lene Wallin; Lene H Iversen; Christina S Gramkow; Mette Okholm; Tine Blemmer; Poul-Erik Svendsen; Henrik H Rottensten; Birgit Thage; Jens Riis; Inge S Jeppesen; Dorthe Teilum; Anne Mette Christensen; Ben Graungaard; Frank Pott
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

Review 2.  [Perioperative fluid management: an analysis of the present situation].

Authors:  Y A Zausig; M A Weigand; B M Graf
Journal:  Anaesthesist       Date:  2006-04       Impact factor: 1.041

3.  [Preoperative fasting times: patients' perspective].

Authors:  L Furrer; M T Ganter; R Klaghofer; A Zollinger; C K Hofer
Journal:  Anaesthesist       Date:  2006-06       Impact factor: 1.041

4.  Clinical benefits after the implementation of a protocol of restricted perioperative intravenous crystalloid fluids in major abdominal operations.

Authors:  José E de Aguilar-Nascimento; Breno N Diniz; Aracelle V do Carmo; Eryka A O Silveira; Raquel M Silva
Journal:  World J Surg       Date:  2009-02-21       Impact factor: 3.352

5.  The menstrual cycle and nausea or vomiting after wisdom teeth extraction.

Authors:  T M Ramsay; P F McDonald; E B Faragher
Journal:  Can J Anaesth       Date:  1994-09       Impact factor: 5.063

6.  Supplemental intravenous crystalloid administration does not reduce the risk of surgical wound infection.

Authors:  Barbara Kabon; Ozan Akça; Akiko Taguchi; Angelika Nagele; Ratnaraj Jebadurai; Cem F Arkilic; Neeru Sharma; Arundhathi Ahluwalia; Susan Galandiuk; James Fleshman; Daniel I Sessler; Andrea Kurz
Journal:  Anesth Analg       Date:  2005-11       Impact factor: 6.627

7.  Supplemental perioperative intravenous crystalloids for postoperative nausea and vomiting.

Authors:  James K Jewer; Michael J Wong; Sally J Bird; Ashraf S Habib; Robin Parker; Ronald B George
Journal:  Cochrane Database Syst Rev       Date:  2019-03-29

8.  Investigation of the effects of preoperative hydration on the postoperative nausea and vomiting.

Authors:  M Selçuk Yavuz; Dilek Kazancı; Sema Turan; Bahar Aydınlı; Gökçe Selçuk; Ayşegül Özgök; Ahmet Coşar
Journal:  Biomed Res Int       Date:  2014-01-20       Impact factor: 3.411

9.  Intravenous fluids for pain management in head and neck cancer patients undergoing chemoradiation.

Authors:  Charlotte I Rivers; Austin J Iovoli; Udit Chatterjee; Gregory M Hermann; Anurag K Singh
Journal:  Ann Transl Med       Date:  2021-05

10.  Intravenous fluid restriction after major abdominal surgery: a randomized blinded clinical trial.

Authors:  Hester Vermeulen; Jan Hofland; Dink A Legemate; Dirk T Ubbink
Journal:  Trials       Date:  2009-07-07       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.